Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Holding KZR?
Track your performance easily
KZR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.20 - $11.35
Previous Close$7.49
Volume35.77K
Average Volume (3M)95.40K
Market Cap
$54.65M
Enterprise Value-$91.92M
Total Cash (Recent Filing)$164.18M
Total Debt (Recent Filing)$17.61M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 13, 2025EPS Estimate
-$2.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.55
Shares Outstanding7,296,222
10 Day Avg. Volume82,943
30 Day Avg. Volume95,401
Standard Deviation0.25
R-Squared0.00212
Alpha0.00259
Financial Highlights & Ratios
Price to Book (P/B)0.32
Price to Sales (P/S)7.75
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-13.13
Enterprise Value/Gross Profit-13.13
Enterprise Value/Ebitda0.97
Forecast
1Y Price Target
$20.00Price Target Upside165.25% Upside
Rating ConsensusHold
Number of Analyst Covering4
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2a PORTOLA trial of zetomipzomib in autoimmune hepatitis completed enrollment early, highlighting a high unmet need and strong treatment demand.
Drug DevelopmentAdvancement of zetomipzomib clinical programs is on track, with the PORTOLA trial progressing ahead of schedule and potentially setting the stage for significant future developments.
Strategic PartnershipsKezar's exclusive licensing agreement with Everest Medicines to develop and commercialize zetomipzomib in Greater China, South Korea, and Southeast Asia enhances its strategic global presence.
Bears Say
Clinical Trial ChallengesThe Investigational New Drug application for zetomipzomib in treating lupus nephritis is on clinical hold by the FDA due to safety concerns, casting doubt on the drug's future.
Financial UncertaintyWith the existing cash burn rate, Kezar Life Sciences might face funding difficulties if they do not secure additional capital, potentially impacting their operations.
Safety ConcernsThe suspension of enrollment and dosing in the PALIZADE trial due to multiple fatal serious adverse events raises significant safety concerns for zetomipzomib.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KZR FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was $5.20 and its highest was $11.35 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Mar 13, 2025 which is in 119 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on Nov 12, 2024. The company reported -$2.78 earnings per share for the quarter, beating the consensus estimate of -$3.148 by $0.368.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -$2.89.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 7,296,222 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -$2.78 in its last earnings report, beating expectations of -$3.148. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Wexford Capital LP. It holds Kezar Life Sciences Inc’s shares valued at N/A.
---
Kezar Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.00 (165.25% Upside)
$20.00 (165.25% Upside)
Blogger Sentiment
Bullish
KZR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.41%
12-Months-Change
Fundamentals
Return on Equity
-51.48%
Trailing 12-Months
Asset Growth
-31.69%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
KZR Stock 12 Month Forecast
Average Price Target
$20.00
▲(165.25% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Corbus Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering KZR
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-14.53%
reiterated a buy rating 3 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -14.53% per trade.
---